Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
2.910
-0.050 (-1.69%)
Sep 20, 2024, 1:19 PM EDT - Market open
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for XERS stock have an average target of 4.67, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 60.48% from the current stock price of 2.91.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 15, 2024.
Analyst Ratings
The average analyst rating for XERS stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +106.19% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +106.19% | May 31, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +3.09% | May 10, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $5 | Buy | Initiates | $5 | +71.82% | Mar 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5.5 → $6 | Strong Buy | Maintains | $5.5 → $6 | +106.19% | Mar 7, 2024 |
Financial Forecast
Revenue This Year
197.27M
from 163.91M
Increased by 20.35%
Revenue Next Year
229.11M
from 197.27M
Increased by 16.14%
EPS This Year
-0.41
from -0.45
EPS Next Year
-0.25
from -0.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 204.5M | 250.9M | 305.3M | ||
| Avg | 197.3M | 229.1M | 272.8M | ||
| Low | 187.6M | 196.1M | 240.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24.8% | 27.2% | 33.3% | ||
| Avg | 20.3% | 16.1% | 19.1% | ||
| Low | 14.4% | -0.6% | 4.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | -0.09 | 0.21 | ||
| Avg | -0.41 | -0.25 | 0.07 | ||
| Low | -0.42 | -0.39 | -0.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.